Abstract
Introduction: stevens–Johnson syndrome is a rare complication of ipilimumab therapy. A brief review of literature on the dermatologic adverse effects of ipilimumab is presented. this paper aims to heighten awareness of the significant risk and potential severity of cutaneous adverse effects associated with the use of ipilimumab. case report: A case of 71-year-old woman being treated with ipilimumab for stage IV choroidal melanoma who presented with stevens–Johnson syndrome 2.5 weeks after her last ipilimumab infusion. conclusion: Delayed diagnosis of stevens–Johnsons syndrome in patients receiving ipilimumab therapy can lead to devastating outcomes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
